Effect of nicotine lozenge use prior to smoking cue presentation on craving and withdrawal symptom severity.

Plain-language guide to PMID 31757519 (2020): randomized controlled trial of Therapeutic nicotine (patch, non-peptide).

Key Facts

PMID: 31757519
Journal: Drug and alcohol dependence
Year: 2020
Study type: Randomized Controlled Trial
Authors: Kotlyar M et al. (5 authors)
DOI: 10.1016/j.drugalcdep.2019.107706

What This Study Did, in Plain Language

What Was Tested

The paper reports a study of Therapeutic nicotine (patch, non-peptide), published as a randomized controlled trial.

Who Took Part

The age groups tagged for this paper are teenagers, young adults, adults and middle-aged adults, both men and women.

In this randomized, cross-over study, participants completed three laboratory sessions at which they proceeded through 4 "rooms" in a virtual reality environment.

How the Study Was Run

The design is described as randomized, placebo-controlled and crossover.

Random assignment meant chance, not the researchers, decided who got Therapeutic nicotine (patch, non-peptide) and who got the comparison, which limits bias.

Some participants received a placebo instead of Therapeutic nicotine (patch, non-peptide), giving a reference point.

Each person switched between Therapeutic nicotine (patch, non-peptide) and the comparison at some point, usually with a gap in between.

The first and last "rooms" contained neutral cues and the others contained smoking cues.

At the other two sessions either a nicotine or placebo lozenge was used 15 min before cue exposure procedures.

Craving and withdrawal symptoms were measured throughout each laboratory session.

What Was Measured

The subject headings attached to it are Craving, Cues, Smoking, Smoking Cessation, Substance Withdrawal Syndrome, Tobacco Use Cessation Devices and Virtual Reality.

Author keywords: Sex differences and Withdrawal symptoms.

What This Means in Plain Language

The paper is a randomized, placebo-controlled and crossover study of Therapeutic nicotine (patch, non-peptide).

The abstract goes on to report its results in about 5 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2020 (Drug and alcohol dependence), a journal based in Ireland.

More context: the Therapeutic nicotine (patch, non-peptide) compound page, all human trials.

Our Notes on the Compound

Therapeutic nicotine (patch, non-peptide): Pure nicotine as a signaling tool, separated from smoking and vaping.

Therapeutic nicotine (patch, non-peptide) in the library

Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.